Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 昆药集团股份有限公司主要经营蒿甲醚系列、三七系列、天麻素系列、秋水仙碱系列、灯盏花系列等名、特、优、新天然药物产品.本公司积极提倡技术创新和新产品开发,充分发挥云南植物王国优势,以丰富的生物资源为基础,以三七产业和蒿甲醚系列产品的深度开发为重点,利用冻干粉针、控释、缓释、微粉等现代高新医药技术开发云南独具特色天然药物产品为主导发展方向,先后开发了30多个具有国内外先进水平的天然药物新产品,其中国家一类新药5个.本公司独家生产的国家一类抗疟疾新药--蒿甲醚系列产品,得到世界卫生组织的高度重视和大力推荐,已列入世界卫生组织的基本药物目录.本公司拥有皂苷类粉针助溶剂、草乌甲素软胶囊生产方法、灯盏花素软胶囊生产方法等9项专利发明。
Main Business 从事药品研发、制造和销售。
Legal Representative 颜炜
Top Executives
董事长：邱华伟
副董事长：颜炜,李泓燊
董事：周辉,郭霆,梁征,李泓燊
独立董事：杨智,辛金国,刘珂
Top 5 Shareholder
Shareholder name Nature Holding Date
华润三九医药股份有限公司流通A股28.04%30/06/2024
云南合和(集团)股份有限公司流通A股7.92%30/06/2024
中国工商银行股份有限公司－富国天惠精选成长混合型证券投资基金（LOF）流通A股3.65%30/06/2024
中国建设银行股份有限公司－工银瑞信前沿医疗股票型证券投资基金流通A股2.18%30/06/2024
中国工商银行股份有限公司－富国研究精选灵活配置混合型证券投资基金流通A股1.91%30/06/2024
Company Secretary 张梦珣
Solicitors 北京德恒（昆明）律师事务所
Auditors 中审亚太会计师事务所（特殊普通合伙）
Tel No 0871-68324311
Fax No 0871-68324267
Website www.kpc.com.cn
Email irm.kpc@kpc.com.cn
Company Address
Register: 云南省昆明市高新技术产业开发区科医路166号
Office: 云南省昆明市国家高新技术开发区科医路166号
Listing Date 06/12/2000
Shares Capital
Shares Capital: 757,113,997
Total A Share: 757,113,997
Listed A Share: 756,975,757
Non-tradable A Share: 138,240
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.590
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 6.989
Market Capitalization(RMB) 9.281B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.